Novo Nordisk rose 1.9% in early Wednesday trading. The company's oral diet drug, Wegovy, is already available in US pharmacies at a cash price of $149-299, and insurance deductibles as low as $25; its competitor Eli Lilly is awaiting approval decisions for its competitive oral therapy.

Novo Nordisk rose 1.9% in early Wednesday trading. The company's oral diet drug, Wegovy, is already available in US pharmacies at a cash price of $149-299, and insurance deductibles as low as $25; its competitor Eli Lilly is awaiting approval decisions for its competitive oral therapy.